We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Eirx Therap. | LSE:ERX | London | Ordinary Share | GB00B0XQBS97 | ORD 0.001P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.015 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:9416O
EiRx Therapeutics PLC
28 February 2008
EIRX THERAPEUTICS PLC ("EiRx" or "the Company")
Holdings in Company
Billam AG has notified the Company that it now holds 721,500,000 EiRx Ordinary
Shares representing 10.3% of the Companies total voting rights.
Billam AG had made 720,500,000 shares, proposed to be acquired in the placing
announced on 19 February 2008, available to satisfy demand from other placees at
the placing price of 0.015p per share.
For further information, please contact:
EiRx Therapeutics plc +353 (0)21 432 0847
Colin Telfer PhD, Chief Executive Officer
Grant Thornton Corporate Finance +44 (0)20 7383 5100
Philip Secrett / Colin Aaronson
About EiRx
EiRx Therapeutics (AIM: ERX) is a research-driven healthcare company developing
cutting-edge targeted therapies for the treatment of cancer. EiRx is
headquartered in Cork, Ireland, conducts drug discovery from its laboratories in
Cork and in Aberdeen, Scotland. The Company has an initial focus on tumours
arising due to anomalies in apoptosis and cellular growth regulatory pathways,
with particular relation to breast and colorectal tumours, currently two of the
four leading causes of death from cancer world-wide.
EiRx is built on leading scientific expertise in the areas of apoptosis biology,
cancer pathway biology, biomarker technologies and the metabolic basis of drug
resistance in tumours. It has established technical capabilities in target
identification, validation and cell-based screening, and is combining unique
resources such as the ACCRI-BANK clinical tissue bank, the ALIBITM functional
genomics platform and the Engineered Pathway Dependence ("EnPADTM") isogenic
cellular screening technology to create a product development engine
specialising in discovery and development of small-molecule targeted cancer
therapies and the discovery and validation of cancer biomarkers.
For further information please see our website at http://www.eirx.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUWURRWORUUAR
1 Year Eirx Therapeutics Chart |
1 Month Eirx Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
